Rexahn Pharmaceuticals (RNN) Given a $20.00 Price Target by HC Wainwright Analysts

Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) has been assigned a $20.00 target price by HC Wainwright in a report issued on Monday. The brokerage currently has a “buy” rating on the stock.

Separately, Zacks Investment Research cut Rexahn Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, January 4th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $13.75.

Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) traded down $0.01 during midday trading on Monday, reaching $1.65. The company had a trading volume of 125,360 shares, compared to its average volume of 402,055. Rexahn Pharmaceuticals has a 12-month low of $1.51 and a 12-month high of $7.10. The stock has a market cap of $51.41, a P/E ratio of -1.77 and a beta of -0.35.

A hedge fund recently bought a new stake in Rexahn Pharmaceuticals stock. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Rexahn Pharmaceuticals, Inc. (NYSEAMERICAN:RNN) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 49,167 shares of the company’s stock, valued at approximately $119,000. Zurcher Kantonalbank Zurich Cantonalbank owned about 0.16% of Rexahn Pharmaceuticals as of its most recent SEC filing.

COPYRIGHT VIOLATION WARNING: “Rexahn Pharmaceuticals (RNN) Given a $20.00 Price Target by HC Wainwright Analysts” was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this story can be viewed at

About Rexahn Pharmaceuticals

Rexahn Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company’s clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance.

Analyst Recommendations for Rexahn Pharmaceuticals (NYSEAMERICAN:RNN)

Receive News & Ratings for Rexahn Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply